Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Cancer
DRUG: Apatinib plus S-1
Progression Free Survival(PFS), Event driven, an expected average of 4 months|Incidence of adverse events, An expected average of 4 months
Overall survival(OS), An expected average of 12months|Disease control rate(DCR), An expected average of 4 months|Objective response rate(ORR), An expected average of 4 months|Quality of life(QoL), An expected average of 12 months
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.